Corixa Corp. and GlaxoSmithKline announced that the companies have reached a settlement with Biogen Idec regarding all outstanding patent litigation between the parties.

The settlement, which serves as the basis for the dismissal of all patent litigation between the parties, provides for Biogen Idec to pay to Corixa and GSK a $20 million upfront settlement payment, as well as a one-time milestone payment based on future Zevalin sales performance, and royalty payments on Zevalin sales from January 1, 2004 until all BEXXAR patents expire. Corixa and GSK will also enter into a worldwide, cross-license agreement with Biogen Idec relating to each party’s patents in suit.

"This is a significant milestone for Corixa, GSK and our stockholders as it concludes the litigation between the companies and provides upfront and future payments to our companies,” stated Steven Gillis, CEO of Corixa.

“We believe this settlement is in the best interests of all parties, and we are pleased to be able to concentrate our future efforts and resources on expanding the market for radioimmunotherapy and bringing BEXXAR to the NHL patients,” stated Kevin Lokay, vice president of oncology at GSK.